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Systemic administration of mesenchymal stem
(stromal) cells (MSCs) has shown benefit in a range of
experimental models of acute kidney injury, although
the reported mechanisms of action and requirement
for MSC localization to the kidney have varied. Geng
and colleagues now demonstrate that a single
intravenous infusion of MSCs given 6 hours after
induction of acute muscle necrosis (rhabdomyolysis)
robustly ameliorates the resulting acute kidney injury and
promotes early intra-renal accumulation of CD206+ (M2)
macrophages. The benefit occurred in the absence of
MSC localization to the kidney and could be reproduced
by adoptive transfer of ex vivo-programmed M2
macrophages.8% to 20% of patients with rhabdomyolysis [3] while theIntroduction
In a recent issue of Stem Cell Research & Therapy, Geng
and colleagues [1] reported that a single intravenous infu-
sion of autologous mesenchymal stem (stromal) cells
(MSCs) given 6 hours after induction of acute muscle ne-
crosis (rhabdomyolysis) in mice robustly ameliorates the
resulting acute kidney injury (AKI). Improvements in kid-
ney function and structure and epithelial cell proliferation
were associated with early intra-renal accumulation of
CD206+ (M2) macrophages and were reversed when
phagocytic cells were eliminated by liposomal clodronate
24 hours after the onset of rhabdomyolysis. Interestingly,
adoptive transfer of mouse macrophages (RAW 264.7
cells) co-cultured with MSCs produced a similar beneficial* Correspondence: matthew.griffin@nuigalway.ie
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12 months following its publication. After this tim
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publicdomain/zero/1.0/) applies to the data mad
2014effect [1]. Thus, the study provides clear evidence that
MSC administration shortly after induction of rhabdo-
myolysis can mediate a strong tissue-protective effect via
re-programming (or ‘alternative activation’) of macro-
phages or their immediate precursor monocytes or both.Mechanisms of action of mesenchymal stem cells
in rhabdomyolysis-associated acute kidney injury
Rhabdomyolysis is frequently associated with AKI as a re-
sult of the release of myoglobin breakdown products (in
particular, ferrihemate) into the bloodstream following the
disintegration of muscle fibers. Individuals may be genet-
ically predisposed to or may acquire rhabdomyolysis as a
result of trauma, drug toxicity, immobilization, or epileptic
seizures [2]. Progression to myoglobinuric AKI occurs in
mortality rate increases from 8% to 10% to as high as 50%
with development of AKI [2]. A key strength of the study
by Geng and colleagues in regard to future clinical transla-
tion is that the timing of MSC administration (6 hours
after intramuscular glycerol injection) is in keeping with
their use by front-line emergency medicine personnel in
victims of trauma or acute illness with evidence of severe
muscle injury.
MSCs are immune-modulatory, plastic-adherent cells
with the capacity to differentiate into chondrocytes, osteo-
blasts, and adipocytes under controlled culture conditions.
In the bone marrow, they constitute part of the perivascu-
lar hematopoietic niche, but they are also present in a
wide range of other adult tissues. MSCs have been re-
ported to protect against AKI in multiple pre-clinical
models, including AKI associated with glycerol-induced
rhabdomyolysis in rodents [1,4-6]. The various proposed
mechanisms for MSC benefits in AKI are discussed in de-
tail in a recent review [7], but it is worth noting that the
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than to their ability to trans-differentiate into functional
renal parenchymal cells. In this regard, an important ex-
perimental finding from the study by Geng and colleagues
is that MSCs did not demonstrably migrate to the injured
kidney within the first 24 hours of induction of rhabdo-
myolysis but were detected in damaged muscle and in the
lungs [1]. This observation is in keeping with an extra-
renal primary site of action of infused MSCs from which
reno-protective effects are mediated by induced soluble
factors (for example, IL-10) and migratory cell populations
(for example, re-programmed monocyte/macrophages)
[8]. Notably, however, previous studies by Herrera and
colleagues [5,6] in which MSCs were administered intra-
venously to mice with glycerol-induced rhabdomyolysis
demonstrated CD44/hyaluronic acid-dependent migration
of MSCs to injured kidney that was associated with en-
hanced renal repair and with MSC engraftment into tubu-
lar epithelium, interstitium, and peritubular capillaries. In
these studies, MSCs were injected at a later time-point
(3 days post-glycerol) than in the study by Geng and col-
leagues, suggesting that timing of administration and per-
haps other factors such as culture conditions, passage
number, and surface receptor profile may significantly in-
fluence in vivo mechanism of action.
Geng and colleagues observed that serum concentra-
tions of IL-10 were increased but that IL-6 and tumor
necrosis factor-alpha were decreased in MSC-treated
mice [1]. Consistent with this shift in archetypal pro-
and anti-inflammatory cytokines, the authors detected
enhanced M2 polarization in the presence of MSCs on
the basis of expression of CD206/mannose receptor.
These findings concur with those of Németh and col-
leagues [8], who demonstrated that increased expression
of IL-10 by MSC-educated macrophages was responsible
for enhanced survival in a sepsis model. In that study,
MSC-derived prostaglandin E2 (PGE2) altered the pheno-
type of activated macrophages via EP2/EP4 receptors [8].
Although the specific roles of PGE2 and IL-10 were not
examined by Geng and colleagues in their model of
rhabdomyolysis-induced AKI, they convincingly demon-
strated the active involvement of macrophage populations
in mediating reno-protection by applying both depletion
and reconstitution strategies at key time-points [1]. An
important role for M2 macrophages in promoting renal
parenchymal repair and regeneration has also been re-
ported in other models of AKI, including unilateral ur-
eteral obstruction, ischemia reperfusion, and adriamycin
nephropathy [9-11]. Although multiple clinically relevant
strategies have been identified in recent years for en-
dogenous or exogenous re-programming of macrophages
toward pro-repair phenotypes, this excellent study by
Geng and colleagues strengthens the case that a single in-
fusion of MSCs can potently expand M2 macrophagenumbers in vivo at a critical time-point during the course
of acute tissue injury.
Though not explicitly discussed by the authors, the fact
that creatine kinase, a biomarker of muscle necrosis, was
also significantly reduced in MSC-treated animals at all
time-points suggests that rhabdomyolysis-associated AKI
may be a particularly attractive therapeutic target for MSC
infusion as a result of a ‘dual effect’ both on the severity of
rhabdomyolysis itself and on the injured kidneys.
Conclusions
As with many other diseases for which pre-clinical
models indicate potential clinical benefit of MSCs in hu-
man subjects, the variances between certain findings of
Geng and colleagues [1] and those reported by others
[5,6] in rhabdomyolysis-associated AKI highlight the
need for further standardization within the field [12].
Conventional laboratory methods for isolating, expand-
ing, and characterizing plastic-adherent MSCs inevitably
result in heterogeneity of administered cells and ideally
would be replaced by selective isolation of defined popu-
lations of cells from bone marrow or other tissues in
order to pinpoint the precise distribution and mechan-
ism(s) of action for a given dose and route of adminis-
tration. Nonetheless, clinical trials of ‘off the shelf ’
MSCs to protect against organ failure in acute rhabdo-
myolysis are theoretically quite feasible and, on the basis
of the results of this well-performed study, may well
have a high likelihood of success.
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